95 related articles for article (PubMed ID: 2275211)
1. Species variation in the response of the cytochrome P-450-dependent monooxygenase system to inducers and inhibitors.
Boobis AR; Sesardic D; Murray BP; Edwards RJ; Singleton AM; Rich KJ; Murray S; de la Torre R; Segura J; Pelkonen O
Xenobiotica; 1990 Nov; 20(11):1139-61. PubMed ID: 2275211
[TBL] [Abstract][Full Text] [Related]
2. Induction of hepatic cytochrome P450 enzymes: methods, mechanisms, recommendations, and in vitro-in vivo correlations.
Hewitt NJ; Lecluyse EL; Ferguson SS
Xenobiotica; 2007; 37(10-11):1196-224. PubMed ID: 17968743
[TBL] [Abstract][Full Text] [Related]
3. Assessment of enzyme induction and enzyme inhibition in humans: toxicological implications.
Park BK; Kitteringham NR
Xenobiotica; 1990 Nov; 20(11):1171-85. PubMed ID: 2275213
[TBL] [Abstract][Full Text] [Related]
4. Sex-dependent metabolism of xenobiotics.
Mugford CA; Kedderis GL
Drug Metab Rev; 1998 Aug; 30(3):441-98. PubMed ID: 9710703
[TBL] [Abstract][Full Text] [Related]
5. Induction of drug-metabolizing enzymes by xenobiotics.
Bock KW; Lipp HP; Bock-Hennig BS
Xenobiotica; 1990 Nov; 20(11):1101-11. PubMed ID: 2125771
[TBL] [Abstract][Full Text] [Related]
6. Cytochrome P450-catalyzed pathways in human brain: metabolism meets pharmacology or old drugs with new mechanism of action?
Haining RL; Nichols-Haining M
Pharmacol Ther; 2007 Mar; 113(3):537-45. PubMed ID: 17270273
[TBL] [Abstract][Full Text] [Related]
7. Steroid hormone biotransformation and xenobiotic induction of hepatic steroid metabolizing enzymes.
You L
Chem Biol Interact; 2004 Apr; 147(3):233-46. PubMed ID: 15135080
[TBL] [Abstract][Full Text] [Related]
8. The duration of induction and species influences the downregulation of cytochrome P450 by the interferon inducer polyinosinic acid-polycytidylic acid.
Anari MR; Cribb AE; Renton KW
Drug Metab Dispos; 1995 May; 23(5):536-41. PubMed ID: 7587927
[TBL] [Abstract][Full Text] [Related]
9. [Cytochrome P-450: structure, function, induction and practical significance].
Monostory K; Lakatos B; Vereczkey L
Acta Pharm Hung; 1992 Nov; 62(6):318-32. PubMed ID: 1488918
[TBL] [Abstract][Full Text] [Related]
10. Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomes.
Kalgutkar AS; Hatch HL; Kosea F; Nguyen HT; Choo EF; McClure KF; Taylor TJ; Henne KR; Kuperman AV; Dombroski MA; Letavic MA
Biopharm Drug Dispos; 2006 Nov; 27(8):371-86. PubMed ID: 16944451
[TBL] [Abstract][Full Text] [Related]
11. The effect of nitrofurazone and furazolidone on induction of cytochrome P-450 dependent monooxygenase system.
Czeczot H; Kobierska-Szeliga M; Bilbin M
Acta Biochim Pol; 1992; 39(1):127-31. PubMed ID: 1441825
[No Abstract] [Full Text] [Related]
12. Role of cytochrome P450 in oxazaphosphorine metabolism. Deactivation via N-dechloroethylation and activation via 4-hydroxylation catalyzed by distinct subsets of rat liver cytochromes P450.
Yu L; Waxman DJ
Drug Metab Dispos; 1996 Nov; 24(11):1254-62. PubMed ID: 8937861
[TBL] [Abstract][Full Text] [Related]
13. Effects of various cytochrome P-450 inducers on testosterone metabolism and several monooxygenase activities in Sprague-Dawley (SpD), high alcohol sensitivity (HAS) and low alcohol sensitivity (LAS) rats.
Duffy O; Berthou F; Bardou LG; Ménez JF
Alcohol Alcohol; 1995 May; 30(3):329-35. PubMed ID: 7545987
[TBL] [Abstract][Full Text] [Related]
14. [Mechanism of inhibiting the cytochrome P-450-dependent monooxygenase system in liver with fluorocarbons].
Obratsov VV; Grishanova AIu; Gudkova OV; Shekhtman DG
Biokhimiia; 1992 Jul; 57(7):1011-20. PubMed ID: 1391210
[TBL] [Abstract][Full Text] [Related]
15. N-aralkyl derivatives of 1-aminobenzotriazole as potent isozyme-selective mechanism-based inhibitors of rabbit pulmonary cytochrome P450 in vivo.
Mathews JM; Bend JR
J Pharmacol Exp Ther; 1993 Apr; 265(1):281-5. PubMed ID: 8474011
[TBL] [Abstract][Full Text] [Related]
16. Toxicological significance of mechanism-based inactivation of cytochrome p450 enzymes by drugs.
Masubuchi Y; Horie T
Crit Rev Toxicol; 2007 Jun; 37(5):389-412. PubMed ID: 17612953
[TBL] [Abstract][Full Text] [Related]
17. Failure in drug development: the role of inhibition and induction of cytochrome P450 enzymes.
Hengstler JG; Bolt HM
Arch Toxicol; 2008 Oct; 82(10):665-6. PubMed ID: 18751968
[No Abstract] [Full Text] [Related]
18. Regulation of CYP4A expression in rat by dehydroepiandrosterone and thyroid hormone.
Webb SJ; Xiao GH; Geoghegan TE; Prough RA
Mol Pharmacol; 1996 Feb; 49(2):276-87. PubMed ID: 8632760
[TBL] [Abstract][Full Text] [Related]
19. Cytochrome P450 polymorphism--molecular, metabolic, and pharmacogenetic aspects. II. Participation of CYP isoenzymes in the metabolism of endogenous substances and drugs.
Tomaszewski P; Kubiak-Tomaszewska G; Pachecka J
Acta Pol Pharm; 2008; 65(3):307-18. PubMed ID: 18646550
[TBL] [Abstract][Full Text] [Related]
20. Effects of chronic exposure to cadmium on renal cytochrome P450-dependent monooxygenase system in rats.
Plewka A; Plewka D; Nowaczyk G; Brzóska MM; Kamiński M; Moniuszko-Jakoniuk J
Arch Toxicol; 2004 Apr; 78(4):194-200. PubMed ID: 14595535
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
